Euveda Biosciences, Inc. is developing innovative platform microfluidic technologies that enable cell-based assays to be performed with unparalleled miniaturization, throughput, and precision. These technologies will have immediate applications in pharmaceutical drug discovery research by enabling promising new drug candidates to be identified using primary cells (cells freshly obtained from humans or animals) more accurately, cheaply, and efficiently. The technology can also be adapted for clinical use for personalized medicine applications. In particular, our technology would allow drug screening to be performed on an individual patient's tumor biopsy cells to identify the optimal chemotherapy drug regimen for that patient, which would fundamentally change the paradigm of cancer treatment.